What is RTGN's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.08B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for RTGN?

P/E (TTM) is n/a and 52-week range is $3.20 to $4.01 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s RTGN figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for RTGN?

The company profile lists net income (TTM) near $-2M, EPS (TTM) near $-0.11 when available from the market-data feed. Figures are informational and may lag live markets.

Where is RetinalGenix Technologies Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Petaluma, California, US, 18.8M shares outstanding, ISIN US76133Y1055 when available from company profile and filing metadata.

Chartloom

RetinalGenix Technologies Inc (RTGN) Stock Analysis & Quote

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

RetinalGeniX Technologies, Inc. operates as a medical device company. The company is headquartered in Petaluma, California. The company went IPO on 2022-01-07. The firm's proprietary High-Resolution Retinal Imaging and DNA/RNA/GPS Pharmaco-Genetic Mapping technologies are designed to help prevent blindness by detecting initial physiological changes that could indicate future ocular and systemic diseases affecting neurodegenerative, cardiovascular, vascular and metabolic systems, as well as diabetic conditions, Alzheimer’s disease and Parkinson’s disease. Its RetinalCam is an in-home/remote location patient-activated monitoring and imaging device offering real-time communication and alerting system for physicians available 24/7. The company is also engaged in the development of its product candidates: RTG-2023 and RTG-2024. RTG-2023 for the treatment of dry age-related macular degeneration (dry AMD). RTG-2024 for the treatment of Alzheimer’s syndrome dementia.

Website

retinalgenix.com/index.php/contact

IPO

2022-01-07

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)